Crinetics Pharmaceuticals, Inc. — Director's Dealing 2020

Feb 26, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Crinetics Pharmaceuticals, Inc. (CRNX)
CIK: 0001658247
Period of Report: 2020-02-24

Reporting Person: Wilson Marc (CFO and Secretary)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-24	Stock Option (right to buy)	$22.61	A	70000	Acquired	2030-02-23	Common Stock (70000)	Direct

Footnotes

F1: The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 24, 2020.